Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study

Matsuyama, Hideyasu; Matsubara, Nobuaki; Kazama, Hirotaka; Seto, Takeshi; Tsukube, Shoko; Suzuki, Kazuhiro

doi:10.1186/s12885-020-07131-6

BMC Cancer

Article metrics
Last updated: Thu, 25 Apr 2024 3:47:59 Z

Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m²) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study

Access & Citations

2364

Article Accesses
3

Web of Science
3

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com